SCHEMBL7018710

SCHEMBL7018710

Cn1c(=O)n(Cc2ccc(F)cc2)c(=O)c2cc(C(=O)O)ncc21

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 2/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
PKM P14618 2/20 0.44
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
TP53 P04637 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
USP1 O94782 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
PARG Q86W56 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7103058 0.90 MMP13 (0.47) MMP13SLC22A8NPSR1MAPTL3MBTL1
SCHEMBL6255569 0.90 MMP13 (0.53) MMP13SLC22A8PKMNPSR1L3MBTL1
SCHEMBL7018972 0.89 GRIN1 (0.44) MMP13SLC22A8PARG
SCHEMBL7097739 0.89 MMP13 (0.46) MMP13SLC22A8PKMNPSR1MAPT
SCHEMBL7102299 0.89 GRIN1 (0.44) MMP13SLC22A8
SCHEMBL7097608 0.88 MAPT (0.47) MMP13SLC22A8MAPTALDH1A1LMNA
SCHEMBL7100732 0.87 PIK3CD (0.51) MMP13SLC22A8PKMMAPTL3MBTL1
SCHEMBL7096688 0.84 RXFP1 (0.44) PKMRXFP1ALDH1A1
SCHEMBL7022157 0.84 MAPT (0.53) MMP13SLC22A8NPSR1MAPTRXFP1
SCHEMBL7014083 0.82 MAPK1 (0.55) MMP13SLC22A8MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
EP-0769940-B1 INDENE sPLA2 INHIBITORS LILLY CO ELI (US) 2003-09-17 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MMP13 1/4885SLC22A8 315/4885PKM 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.